What is Efracea 40mg Modified Release Hard Capsules?
Efracea 40mg Modified Release Hard Capsules is a tetracycline antibiotic that fights bacteria in the body.
Efracea 40mg Modified Release Hard Capsules is used to treat many different bacterial infections, such as acne, urinary tract infections, intestinal infections, eye infections, gonorrhea, chlamydia, periodontitis (gum disease), and others.
Efracea 40mg Modified Release Hard Capsules is also used to treat blemishes, bumps, and acne-like lesions caused by rosacea. Efracea 40mg Modified Release Hard Capsules will not treat facial redness caused by rosacea.
Some forms of Efracea 40mg Modified Release Hard Capsules are used to prevent malaria, to treat anthrax, or to treat infections caused by mites, ticks, or lice.
Efracea 40mg Modified Release Hard Capsules may also be used for purposes not listed in this medication guide.
Efracea 40mg Modified Release Hard Capsules indications
Rickettsial Infections
Efracea 40mg Modified Release Hard Capsules® and Efracea 40mg Modified Release Hard Capsules® CAP are indicated for treatment of Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsial pox, and tick fevers caused by Rickettsiae.
Sexually Transmitted Infections
Efracea 40mg Modified Release Hard Capsules and Efracea 40mg Modified Release Hard Capsules CAP are indicated for treatment of the following sexually transmitted infections:
- Uncomplicated urethral, endocervical or rectal infections caused by Chlamydia trachomatis.
- Nongonococcal urethritis caused by Ureaplasma urealyticum.
- Lymphogranuloma venereum caused by Chlamydia trachomatis.
- Granuloma inguinale caused by Klebsiella granulomatis.
- Uncomplicated gonorrhea caused by Neisseria gonorrhoeae.
- Chancroid caused by Haemophilus ducreyi.
Respiratory Tract Infections
Efracea 40mg Modified Release Hard Capsules and Efracea 40mg Modified Release Hard Capsules CAP are indicated for treatment of the following respiratory tract infections:
- Respiratory tract infections caused by Mycoplasma pneumoniae.
- Psittacosis (ornithosis) caused by Chlamydophila psittaci.
- Because many strains of the following groups of microorganisms have been shown to be resistant to Efracea 40mg Modified Release Hard Capsules, culture and susceptibility testing are recommended.
- Efracea 40mg Modified Release Hard Capsules is indicated for treatment of infections caused by the following microorganisms, when bacteriological testing indicates appropriate susceptibility to the drug:
- Respiratory tract infections caused by Haemophilus influenzae.
- Respiratory tract infections caused by Klebsiella species.
- Upper respiratory infections caused by Streptococcus pneumoniae.
Specific Bacterial Infections
Efracea 40mg Modified Release Hard Capsules and Efracea 40mg Modified Release Hard Capsules CAP are indicated for treatment of the following specific bacterial infections:
- Relapsing fever due to Borrelia recurrentis.
- Plague due to Yersinia pestis.
- Tularemia due to Francisella tularensis.
- Cholera caused by Vibrio cholerae.
- Campylobacter fetus infections caused by Campylobacter fetus.
- Brucellosis due to Brucella species (in conjunction with streptomycin).
- Bartonellosis due to Bartonella bacilliformis.
Because many strains of the following groups of microorganisms have been shown to be resistant to Efracea 40mg Modified Release Hard Capsules, culture and susceptibility testing are recommended.
Efracea 40mg Modified Release Hard Capsules and Efracea 40mg Modified Release Hard Capsules CAP are indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriological testing indicates appropriate susceptibility to the drug:
- Escherichia coli
- Enterobacter aerogenes
- Shigella species
- Acinetobacter species
- Urinary tract infections caused by Klebsiella species.
Ophthalmic Infections
Efracea 40mg Modified Release Hard Capsules and Efracea 40mg Modified Release Hard Capsules CAP are indicated for treatment of the following ophthalmic infections:
- Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence.
- Inclusion conjunctivitis caused by Chlamydia trachomatis.
Anthrax Including Inhalational Anthrax (Post-Exposure)
Efracea 40mg Modified Release Hard Capsules and Efracea 40mg Modified Release Hard Capsules CAP are indicated for the treatment of Anthrax due to Bacillus anthracis, including inhalational anthrax (post-exposure); to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis.
Alternative Treatment for Selected Infections when Penicillin is Contraindicated
Efracea 40mg Modified Release Hard Capsules and Efracea 40mg Modified Release Hard Capsules CAP are indicted as an alternative treatment for the following selected infections when penicillin is contraindicated:
- Syphilis caused by Treponema pallidum.
- Yaws caused by Treponema pallidum subspecies pertenue.
- Listeriosis due to Listeria monocytogenes.
- Vincent’s infection caused by Fusobacterium fusiforme.
- Actinomycosis caused by Actinomyces israelii.
- Infections caused by Clostridium species.
Adjunctive Therapy for Acute Intestinal Amebiasis and Severe Acne
In acute intestinal amebiasis, Efracea 40mg Modified Release Hard Capsules and Efracea 40mg Modified Release Hard Capsules CAP may be a useful adjunct to amebicides.
In severe acne, Efracea 40mg Modified Release Hard Capsules and Efracea 40mg Modified Release Hard Capsules CAP may be useful adjunctive therapy.
Prophylaxis of Malaria
Efracea 40mg Modified Release Hard Capsules and Efracea 40mg Modified Release Hard Capsules CAP are indicated for the prophylaxis of malaria due to Plasmodium falciparum in short-term travelers (less than 4 months) to areas with chloroquine and/or pyrimethamine-sulfadoxine resistant strains.
Usage
To reduce the development of drug-resistant bacteria and maintain the effectiveness of Efracea 40mg Modified Release Hard Capsules and Efracea 40mg Modified Release Hard Capsules CAP and other antibacterial drugs, Efracea 40mg Modified Release Hard Capsules and Efracea 40mg Modified Release Hard Capsules CAP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
How should I use Efracea 40mg Modified Release Hard Capsules?
Use Efracea 40mg Modified Release Hard Capsules tablets as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- Take Efracea 40mg Modified Release Hard Capsules tablets by mouth on an empty stomach at least 1 hour before or 2 hours after eating.
- Do not take an antacid that has aluminum, calcium, or magnesium in it; bismuth subsalicylate; iron; zinc; or multivitamins with minerals within 2 hours before or 2 hours after you take Efracea 40mg Modified Release Hard Capsules tablets.
- Do not eat or drink dairy products within 1 hour before or 2 hours after you take Efracea 40mg Modified Release Hard Capsules tablets.
- To clear up your infection completely, take Efracea 40mg Modified Release Hard Capsules tablets for the full course of treatment. Keep taking it even if you feel better in a few days.
- Drink plenty of nondairy fluid with Efracea 40mg Modified Release Hard Capsules tablets to wash it down and avoid the risk of sore throat.
- Take Efracea 40mg Modified Release Hard Capsules tablets twice daily (every 12 hours), preferably in the morning and evening.
- Continue to take Efracea 40mg Modified Release Hard Capsules tablets even if you feel well. Do not miss any doses.
- If you miss a dose of Efracea 40mg Modified Release Hard Capsules tablets, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.
Ask your health care provider any questions you may have about how to use Efracea 40mg Modified Release Hard Capsules tablets.
Uses of Efracea 40mg Modified Release Hard Capsules in details
Use: Labeled Indications
Acne: Adjunctive therapy in severe acne.
Actinomycosis: Treatment of actinomycosis caused by Actinomyces israelii when penicillin is contraindicated.
Acute intestinal amebiasis: Adjunct to amebicides in acute intestinal amebiasis.
Anthrax, including inhalational anthrax (postexposure): Treatment of anthrax caused by Bacillus anthracis, including inhalational (postexposure) prophylaxis; to reduce the incidence or progression of disease following exposure to aerosolized B. anthracis.
Cholera: Treatment of cholera infections caused by Vibrio cholerae.
Clostridium: Treatment of infections caused by Clostridium spp. when penicillin is contraindicated.
Gram-negative infections: Treatment of infections caused by Escherichia coli, Enterobacter aerogenes, Shigella spp., Acinetobacter spp., Klebsiella spp. (respiratory and urinary infections), and Bacteroides spp.; Neisseria meningitidis (when penicillin is contraindicated).
Gram-positive infections: Treatment of infections caused by Streptococcus spp., when susceptible.
Listeriosis: Treatment of listeriosis due to Listeria monocytogenes when penicillin is contraindicated.
Malaria prophylaxis: Prophylaxis of malaria due to Plasmodium falciparum in short-term travelers (under 4 months) to areas with chloroquine and/or pyrimethamine-sulfadoxine-resistant strains.
Mycoplasma pneumoniae: Treatment of infections caused by Mycoplasma pneumoniae.
Ophthalmic infections:
Treatment of inclusion conjunctivitis or trachoma caused by Chlamydia trachomatis.
Periodontitis (20 mg tablet and capsule [Efracea 40mg Modified Release Hard Capsules (Canadian product)] only): Adjunct to scaling and root planing to promote attachment level gain and to reduce pocket depth in patients with adult periodontitis.
Relapsing fever: Treatment of relapsing fever caused by Borrelia recurrentis.
Respiratory tract infections: Treatment of respiratory infections caused by Haemophilus influenzae, Klebsiella spp., or Mycoplasma pneumoniae; treatment of upper respiratory tract infections caused by Streptococcus pneumoniae; respiratory infections caused by Staphylococcus aureus (Efracea 40mg Modified Release Hard Capsules is not the drug of choice in the treatment of any type of staphylococcal infection).
Rickettsial infections: Treatment of Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae.
Rosacea (Efracea 40mg Modified Release Hard Capsules, Apprilon [Canadian product] only): Treatment of only inflammatory lesions (papules and pustules) of rosacea in adults.
Sexually transmitted infections: Treatment of lymphogranuloma venereum and uncomplicated urethral, endocervical, or rectal infections caused by Chlamydia trachomatis; granuloma inguinale (donovanosis) caused by Klebsiella granulomatis; chancroid caused by Haemophilus ducreyi; nongonococcal urethritis caused by Ureaplasma urealyticum; when penicillin is contraindicated, uncomplicated gonorrhea caused by Neisseria gonorrhea and syphilis caused by Treponema pallidum.
Note: The CDC sexually transmitted disease guidelines recommend dual antimicrobial therapy be used for uncomplicated gonorrhea due to N. gonorrhea resistance concerns; ceftriaxone is the preferred cephalosporin and Efracea 40mg Modified Release Hard Capsules is an alternative option for the second antimicrobial only in cases of azithromycin allergy (CDC [Workowski 2015]).
Skin and skin structure infections (Avidoxy only): Treatment of skin and skin structure infections caused by Staphylococcus aureus (Efracea 40mg Modified Release Hard Capsules is not the drug of choice in the treatment of any type of staphylococcal infection).
Vincent infection: Treatment of Vincent infection caused by Fusobacterium fusiforme when penicillin is contraindicated.
Yaws: Treatment of yaws caused by Treponema pallidum subspecies pertenue when penicillin is contraindicated.
Zoonotic infections: Treatment of psittacosis (ornithosis) caused by Chlamydophila psittaci; plague due to Yersinia pestis; tularemia caused by Francisella tularensis; brucellosis caused by Brucella spp. (in conjunction with streptomycin); bartonellosis caused by Bartonella bacilliformis; infections caused by Campylobacter fetus.
Off Label Uses
Anaplasmosis and ehrlichiosis
Based on the IDSA guidelines for the clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis (HGA) and babesiosis and the Centers for Disease Control and Prevention (CDC) guideline for the diagnosis and management of tickborne rickettsial diseases, Efracea 40mg Modified Release Hard Capsules is effective and recommended for the treatment of human anaplasmosis (also known as HGA) and human ehrlichiosis.
Bartonella infections in HIV-infected patients
Based on the US Department of Health and Human Services (HHS) guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents, Efracea 40mg Modified Release Hard Capsules is a recommended and effective agent for treatment of bacillary angiomatosis, peliosis hepatis, bacteremia, osteomyelitis, CNS infections, infective endocarditis, and other severe infections due to Bartonella in adolescent and adult HIV-infected patients.
Bite wound infection (animal or human bite)
Based on the IDSA guidelines for the diagnosis and management of SSTIs, Efracea 40mg Modified Release Hard Capsules is an acceptable alternative agent for the prophylaxis and treatment of bite wounds (animal or human).
Cellulitis, mild to moderate
Based on the Infectious Diseases Society of America (IDSA) guidelines for the diagnosis and management of skin and soft tissue infections (SSTIs) and the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections, Efracea 40mg Modified Release Hard Capsules is an effective and recommended treatment option for SSTIs caused by MRSA, particularly purulent cellulitis due to community-acquired MRSA (CA-MRSA).
Chronic obstructive pulmonary disease, acute exacerbation
Data from a randomized, double-blind, placebo-controlled trial support the use of Efracea 40mg Modified Release Hard Capsules in the treatment of acute exacerbation of chronic obstructive pulmonary disease (COPD).
Based on the American College of Chest Physicians diagnosis and management of lung cancer clinical practice guidelines, intrapleural Efracea 40mg Modified Release Hard Capsules is effective and recommended in the management of recurrent, symptomatic, malignant pleural effusions.
Proctitis, acute or proctocolitis
Based on the CDC sexually transmitted diseases treatment guidelines, Efracea 40mg Modified Release Hard Capsules in combination with ceftriaxone is an effective and recommended agent in the treatment of acute proctitis or proctocolitis.
Prosthetic joint infection
Based on the IDSA guidelines for the management of prosthetic joint infection, Efracea 40mg Modified Release Hard Capsules is an effective and recommended agent for treatment (oral phase) of prosthetic joint infection and for chronic oral antimicrobial suppression of prosthetic joint infection due to staphylococci or Cutibacterium acnes.
Surgical prophylaxis, uterine evacuation (induced abortion or pregnancy loss)
Based on the American College of Obstetricians and Gynecologists guidelines for prevention of infection after gynecologic procedures, Efracea 40mg Modified Release Hard Capsules is effective and recommended as antimicrobial prophylaxis for uterine evacuation procedures for induced abortion or pregnancy loss.
Efracea 40mg Modified Release Hard Capsules description
Efracea 40mg Modified Release Hard Capsules is a broad-spectrum antibiotic synthetically derived from oxytetracycline and is available as Efracea 40mg Modified Release Hard Capsules monohydrate and Efracea 40mg Modified Release Hard Capsules hyclate (hydrochloride hemiethanolate hemihydrate). The chemical designation of this light-yellow crystalline powder is α-6-deoxy-5-oxytetracycline. Efracea 40mg Modified Release Hard Capsules has a high degree of lipoid solubility and a low affinity for calcium binding. It is highly stable in normal human serum. Efracea 40mg Modified Release Hard Capsules will not degrade into an epianhydro form.
The molecular formula for Efracea 40mg Modified Release Hard Capsules hydrochloride hemiethanolate hemihydrate is (C22H24N2O8·HCl)2·C2H6O·H2O and the molecular weight is 1025.89. Efracea 40mg Modified Release Hard Capsules is a light-yellow crystalline powder. Efracea 40mg Modified Release Hard Capsules hyclate is soluble in water, while Efracea 40mg Modified Release Hard Capsules monohydrate is very slightly soluble in water.
Efracea 40mg Modified Release Hard Capsules dosage
THE DOSAGE OF Efracea 40mg Modified Release Hard Capsules® (Efracea 40mg Modified Release Hard Capsules hyclate) DIFFERS FROM THAT OF Efracea 40mg Modified Release Hard Capsules USED TO TREAT INFECTIONS. EXCEEDING THE RECOMMENDED DOSAGE MAY RESULT IN AN INCREASED INCIDENCE OF SIDE EFFECTS INCLUDING THE DEVELOPMENT OF RESISTANT MICROORGANISMS.
Efracea 40mg Modified Release Hard Capsules® (Efracea 40mg Modified Release Hard Capsules hyclate) 20 mg twice daily as an adjunct following scaling and root planing may be administered for up to 9 months. Efracea 40mg Modified Release Hard Capsules® (Efracea 40mg Modified Release Hard Capsules hyclate) should be taken twice daily at 12 hour intervals, usually in the morning and evening. It is recommended that if Efracea 40mg Modified Release Hard Capsules® (Efracea 40mg Modified Release Hard Capsules hyclate) is taken close to meal times, allow at least one hour prior to or two hours after meals. Safety beyond 12 months and efficacy beyond 9 months have not been established.
Administration of adequate amounts of fluid along with the tablets is recommended to wash down the drug and reduce the risk of esophageal irritation and ulceration..
How supplied
Efracea 40mg Modified Release Hard Capsules® (Efracea 40mg Modified Release Hard Capsules hyclate) (white tablet imprinted with a PS20) containing Efracea 40mg Modified Release Hard Capsules hyclate equivalent to 20 mg Efracea 40mg Modified Release Hard Capsules. Bottle of 60 (NDC 64682-008-01), Bottle of 100 (NDC 64682-008-02) and Bottle of 1000 (NDC 64682-008-03).
Storage: All products are to be stored at controlled room temperatures of 15°C - 30°C (59°F - 86°F) and dispensed in tight, light-resistant containers (USP).
Manufactured by: Pharmaceutical Manufacturing Research Services, Inc., Horsham, PA 19044. Marketed by: CollaGenex Pharmaceuticals, Inc., Newtown, PA, 18940. FDA revision date: 3/31/2004
Efracea 40mg Modified Release Hard Capsules interactions
See also:
What other drugs will affect Efracea 40mg Modified Release Hard Capsules?
Medications containing metal ions (antacids, products containing iron, magnesium, calcium) form inactive chelates with Efracea 40mg Modified Release Hard Capsules, in connection with what it is necessary to avoid their simultaneous use.
It needed to avoid combination with penicillins, cephalosporins, bactericidal action and is an antagonist of bacteriostatic antibiotics (including Efracea 40mg Modified Release Hard Capsules).
Absorption of Efracea 40mg Modified Release Hard Capsules is reduced by cholestyramine and colestipol (observe the interval between the reception of at least 3 h).
Due to suppression of intestinal microflora Efracea 40mg Modified Release Hard Capsules reduces prothrombin index which requires dose adjustment of indirect anticoagulants.
Alti-Efracea 40mg Modified Release Hard Capsules reduces the reliability of contraception and increases the frequency of breakthrough bleeding while taking estrogen-containing oral contraceptives.
Simultaneous administration of Alti-Efracea 40mg Modified Release Hard Capsules with:
Efracea 40mg Modified Release Hard Capsules side effects
See also:
What are the possible side effects of Efracea 40mg Modified Release Hard Capsules?
Clinical Trial Experience
The safety and efficacy of Efracea 40mg Modified Release Hard Capsules Hyclate Delayed-Release Tablets, 200 mg as a single daily dose was evaluated in a multicenter, randomized, double-blind, active-controlled study. Efracea 40mg Modified Release Hard Capsules Hyclate Delayed-Release Tablets 200 mg was given orally once-a-day for 7 days and compared to Efracea 40mg Modified Release Hard Capsules hyclate capsules 100 mg given orally twice daily for 7 days for the treatment of men and women with uncomplicated urogenital C. trachomatis infection.
Adverse events in the Safety Population were reported by 99 (40.2%) subjects in the Efracea 40mg Modified Release Hard Capsules Hyclate Delayed-Release Tablets, 200 mg treatment group and 132 (53.2%) subjects in the doxycyclinehyclate capsules reference treatment group. Most AEs were mild in intensity. The most commonly reported adverse events in both treatment groups were nausea, vomiting, diarrhea, and bacterial vaginitis, Table 1.
Table 1: Adverse Reactions Reported in Greater than or Equal to 2% of Subjects
| Efracea 40mg Modified Release Hard Capsules Hyclate Delayed-Release Tablets, 200 mg N = 246 | |
| Preferred Term | n (%) |
| Subjects with any AE | 99 (40.2) |
| Nausea | 33 (13.4) |
| Vomiting | 20 (8.1) |
| Headache | 5 (2.0) |
| Diarrhea | 8 (3.3) |
| Abdominal Pain Upper | 5 (2.0) |
| Vaginitis Bacterial | 8 (3.3) |
| Vulvovaginal Mycotic Infection | 5 (2.0) |
Because clinical trials are conducted under prescribed conditions, adverse reaction rates observed in the clinical trial may not always reflect the rates observed in practice.
Postmarketing Experience
The following adverse reactions have been identified during post-approval use of Efracea 40mg Modified Release Hard Capsules. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate a causal relationship to drug exposure.
Due to oral Efracea 40mg Modified Release Hard Capsules's virtually complete absorption, side effects to the lower bowel, particularly diarrhea, have been infrequent. The following adverse reactions have been observed in patients receiving tetracyclines:
Gastrointestinal: Anorexia, nausea, vomiting, diarrhea, glossitis, dysphagia, enterocolitis, and inflammatory lesions (with monilial overgrowth) in the anogenital region. Hepatotoxicity has been reported. These reactions have been caused by both the oral and parenteral administration of tetracyclines. Esophagitis and esophageal ulcerations have been reported in patients receiving capsule and tablet forms of drugs in the tetracycline-class. Most of these patients took medications immediately before going to bed.
Skin: Maculopapular and erythematous rashes, Stevens-Johnson syndrome, toxic epidermal necrolysis, exfoliative dermatitis, and erythema multiforme have been reported. Photosensitivity is discussed above.
Renal: Rise in BUN has been reported and is apparently dose-related.
Hypersensitivity reactions: Urticaria, angioneurotic edema, anaphylaxis, anaphylactoid purpura, serum sickness, pericarditis, and exacerbation of systemic lupus erythematosus.
Blood: Hemolytic anemia, thrombocytopenia, neutropenia, and eosinophilia have been reported.
Intracranial Hypertension: Intracranial hypertension (IH, pseudotumor cerebri) has been associated with the use of tetracycline
Thyroid Gland Changes: When given over prolonged periods, tetracyclines have been reported to produce brown-black microscopic discoloration of thyroid glands. No abnormalities of thyroid function are known to occur.
Efracea 40mg Modified Release Hard Capsules contraindications
Do not use this medicine if you are pregnant. It could harm the unborn baby or cause permanent tooth discoloration later in life.
Efracea 40mg Modified Release Hard Capsules can make birth control pills less effective. Ask your doctor about using a non hormone method of birth control (such as a condom, diaphragm, spermicide) to prevent pregnancy while using Efracea 40mg Modified Release Hard Capsules.
You should not take this medicine if you are allergic to Efracea 40mg Modified Release Hard Capsules or to other tetracycline antibiotics such as demeclocycline (Declomycin), minocycline (Dynacin, Minocin, Solodyn, Vectrin), or tetracycline (Brodspec, Panmycin, Sumycin, Tetracap).
Before taking Efracea 40mg Modified Release Hard Capsules, tell your doctor if you have liver disease, kidney disease, asthma, or if you are allergic to sulfites.
Drink plenty of liquids while you are taking Efracea 40mg Modified Release Hard Capsules.
Children should not use Efracea 40mg Modified Release Hard Capsules. Efracea 40mg Modified Release Hard Capsules can cause permanent yellowing or graying of the teeth in children younger than 8 years old.
Take this medication for the full prescribed length of time. Your symptoms may improve before the infection is completely cleared. Skipping doses may also increase your risk of further infection that is resistant to antibiotics.
Active ingredient matches for Efracea 40mg Modified Release Hard Capsules:
Doxycycline in United Kingdom.
List of Efracea 40mg Modified Release Hard Capsules substitutes (brand and generic names) | Sort by popularity |
| Unit description / dosage (Manufacturer) | Price, USD |
| Efracea (United Kingdom) | |
| Elidoxx (Peru) | |
| EMDOX (India) | |
| 100 mg x 140's (Madhav Biotech) | $ 5.06 |
| Emdox 100mg DT-TAB / 140 (Madhav Biotech) | $ 5.06 |
| EMDOX dispertab 100 mg x 14's (Madhav Biotech) | $ 0.51 |
| Emdox 100mg DT-TAB / 140 (Madhav Biotech) | $ 5.06 |
| Epidox (Pakistan) | |
| Epidox 10mg VIAL / 1 (Samarth) | $ 6.02 |
| Epidox 50mg VIAL / 1 (Samarth) | $ 27.59 |
| 10 mg x 1's (Samarth) | $ 6.02 |
| 50 mg x 1's (Samarth) | $ 27.59 |
| EPIDOX 10MG INJECTION 1 vial / 1 injection each (Samarth) | $ 6.31 |
| EPIDOX 50MG INJECTION 1 vial / 1 injection each (Samarth) | $ 37.01 |
| EPIDOX inj 10 mg x 1's (Samarth) | $ 6.02 |
| EPIDOX inj 50 mg x 1's (Samarth) | $ 27.59 |
| Epidox 10mg Injection (Samarth) | $ 6.31 |
| Epidox 50mg Injection (Samarth) | $ 37.01 |
| Esadoxi (Italy) | |
| Esteveciclina (Portugal) | |
| Ethidox (Pakistan) | |
| Etidoxina (Colombia) | |
| Etidoxina 100 (Colombia) | |
| Etidoxine (Pakistan) | |
| Exmycin (Pakistan) | |
| Farcodoxin (Egypt) | |
| Fardox (Bangladesh) | |
| Farmodoxi (Lebanon) | |
| Fatrociclina (Italy) | |
| Fenseptyl (Pakistan) | |
| Frakas (Australia) | |
| Tablet; Oral; Doxycycline 50 mg (Arrow) | |
| Tablets; Oral; Doxycycline 50 mg (Arrow) | |
| G DOX | |
| G DOX CAPSULE 1 strip / 20 capsules each (Ind Swift Laboratories Ltd) | $ 0.09 |
| GalluDoxx (United Kingdom) | |
| Galludoxx 500 mg/g voor kalveren, kippen en kalkoenen (Netherlands) | |
| Geeox (India) | |
| GEEOX Capsule/ Tablet / 100mg / 10 units (Genstar (Cadila Pharmaceuticals Ltd.)) | $ 0.10 |
| Geeox 100mg CAP / 10 (Genstar (Cadila Pharmaceuticals Ltd.)) | $ 0.11 |
| Capsules; Oral; Doxycycline 100 mg (Genstar (Cadila Pharmaceuticals Ltd.)) | |
| 100 mg x 10's (Genstar (Cadila Pharmaceuticals Ltd.)) | $ 0.11 |
| Geeox 100 mg Capsule (Genstar (Cadila Pharmaceuticals Ltd.)) | $ 0.01 |
| GEEOX cap 100 mg x 10's (Genstar (Cadila Pharmaceuticals Ltd.)) | $ 0.11 |
| GenRX Doxycycline (Australia) | |
| GenRx Doxycycline Capsules | |
| Capsule; Oral; Doxycycline Hydrochloride 100 mg | |
| Capsule; Oral; Doxycycline Hydrochloride 50 mg | |
See 2106 substitutes for Efracea 40mg Modified Release Hard Capsules | |
References
- DailyMed. "DOXYCYCLINE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- PubChem. "doxycycline". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
- DrugBank. "doxycycline". http://www.drugbank.ca/drugs/DB00254 (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Efracea 40mg Modified Release Hard Capsules are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Efracea 40mg Modified Release Hard Capsules. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported useful
No survey data has been collected yetConsumer reported price estimates
No survey data has been collected yetConsumer reported time for results
No survey data has been collected yetConsumer reported age
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
